首页|Statin pretreatment combined with intravenous thrombolysis for ischemic stroke patients: A meta-analysis
Statin pretreatment combined with intravenous thrombolysis for ischemic stroke patients: A meta-analysis
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
? 2022 Elsevier LtdPurpose: For ischemic stroke patients, thrombolysis therapy combined statins might have a better benefit. But difference studies had a debate. The meta-analysis wants to make clear about whether statins could increase effect of therapy or decrease side effect for these patients. Methods objectives: To evaluate the effect and safety about using statins in ischemic stroke patients receiving thrombolysis. Data sources: Databases including PubMed, Web of Science, Embase and Cochrane Library. Eligibility criteria: original observational cohort studies. Participants: ischemic stroke patients receiving thrombolysis. Interventions: pretreatment statins. Appraisal and synthesis methods: forest plot to show pooled results; I-squared test to evaluate the heterogeneity. Results: Of 87 selected, 8 were eligible. The 8 studies included 10,344 patients (with statins: 2048; without statins: 8296). For clinical recovery at 24 h, pooled OR (odds ratios) was 1.82 (95% CI: 1.49–2.21). For excellent outcome, pooled OR was 1.03 (95% CI: 0.80–1.12). For favorable outcome, pooled OR was 0.99 (95% CI: 0.85–1.16). For ICH (intracranial hemorrhage), pooled OR was 1.16 (95% CI: 0.97–1.40). For sICH (symptomatic intracranial hemorrhage), pooled OR was 1.40 (95% CI: 1.02–1.91). For mortality, overall pooled OR was 0.96 (95% CI: 0.74–1.25). Conclusion: In conclusion, the meta-analysis found that for ischemic stroke patients receiving thrombolysis, pretreatment statins were related to a better clinical recovery and a lower short-term mortality. Pretreatment statins had no significant relationship with mRS at 90 days and ICH. Pretreatment high dose statins may be related to the occurrence of sICH.
NSTL
Elsevier
